For the quarter ending 2026-03-31, GANX had -$4,298,617 decrease in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -5,608,732 | -4,537,581 | -5,284,373 | -10,339,145 |
| Depreciation and amortization | 21,303 | 28,241 | 22,817 | 42,988 |
| Stock-based compensation expense | 403,509 | 401,667 | 460,005 | 941,523 |
| Other non-cash items | -230,462 | -11,194 | -10,864 | -782,880 |
| Prepaid expenses and other current assets | 278,213 | -304,426 | -866,395 | 1,252,940 |
| Long term deposit and other noncurrent assets | 913 | -533 | -541 | -1,778 |
| Defined benefit pension plan | - | - | -35,307 | -68,395 |
| Deferred grant income | - | -14,843 | -18,239 | -294,989 |
| Accounts payable and other current liabilities | 531,767 | -785,258 | -949,139 | 1,265,791 |
| Defined benefit pension plan | -26,710 | -130,568 | - | - |
| Total changes in operating assets and liabilities | -225,931 | 522,008 | 135,749 | 348,755 |
| Cash used in operating activities | -4,727,527 | -4,618,487 | -4,926,436 | -8,920,509 |
| Net proceeds from issuance of shares in 2024 atm program (note 13) | 427,783 | 13,149,139 | 0 | 4,910,240 |
| Net proceeds from issuance of shares in public offering (note 14) | - | 0 | 7,411,554 | - |
| Net proceeds from the exercise of warrants (note 13) | 2,063 | 3,176,807 | 41,745 | - |
| Net proceeds from the exercise of stock options (note 15) | - | 250,260 | - | - |
| Payments of offering costs (note 14) | - | 0 | 395,478 | - |
| Payments of current portion of long-term debt (note 11) | 25,525 | 25,025 | 24,996 | 46,480 |
| Cash provided by financing activities | 404,321 | 16,551,181 | 7,032,825 | 4,863,760 |
| Effect of exchange rate changes | 24,589 | 97,760 | 6,667 | 369,605 |
| Net decrease in cash, cash equivalents and restricted cash | -4,298,617 | 12,030,454 | 2,113,056 | -3,687,144 |
| Cash, cash equivalents and restricted cash at beginning of period | 20,873,924 | 8,843,470 | 10,417,558 | - |
| Cash, cash equivalents and restricted cash at end of period | 16,575,307 | 20,873,924 | 8,843,470 | - |
Gain Therapeutics, Inc. (GANX)
Gain Therapeutics, Inc. (GANX)